Response to Comments: MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer

This document is an administrative Response to Comments regarding MolDX: Inivata, InVisionFirst liquid biopsy for lung cancer (DL37899) and provides notice period and finalization dates. The provided text contains no clinical coverage criteria, limitations, frequency limits, or claim documentation requirements; consult the final LCD DL37899 (effective 06/03/2019) for substantive coverage rules.

"This document is a Response to Comments for MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer (DL37899); comment period 10/04/2018–12/14/2018, notice period 04/18/2019–06/0..."

Sign up to see full coverage criteria, indications, and limitations.